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The light  (L) polypeptide  chains  of the human T-globulins  carry antigenic 
determinants  designated  as group  1 or 2  (1-3).  Allotypic determinants  desig- 
nated InV have been found in association with the L  chains of 3,,-globulin (4). 
Naturally  occurring human  antibody  directed  toward  L  chain  determinants 
has been described in detail only for the InV antigens  (5). 
The present studies utilize human Bence Jones (B  J) proteins which, in their 
primary structure, appear to be identical with the L chains of the several human 
?-globulins  but  are  entirely  of either  group  1  or  2  antigenic  specificity  (1). 
Tannic acid-treated sheep erythrocytes coated with highly purified group 1 or 
2  Bence  Jones  proteins  detect  naturally  occurring human  antibody  directed 
toward L chain determinants  which appear to be blocked in intact "y-globulins 
by the heavy (H) polypeptide chains. 
Materials and Methods 
Benc.e Jones Proteins  1.-Bence Jones proteins were isolated from the urines of patients with 
multiple myeloma and macroglobulinemia. The isolation of Bence Jones protein 39 from the 
urine of a patient with Waidenstr~m's macroglobulinemia has been described previously  (6). 
Two urines containing Bence Jones proteins 40 and 43 were dialyzed against water, and then 
0.01 x, phosphate, pH 8. These BJ proteins were partially purified by stepwise or a salt gradient 
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1 Salts, buffers, and reagents: Reagent grade acetic acid, sodium acetate, and sodium phos- 
phate were used for the preparation  of buffers. Mercaptoethanol  (California Corp. for Bio- 
chemical Research,  Los Angeles) and  iodoacetamide  (Mann  Research  Laboratories,  New 
York) were used without further purification. Carboxymethyl and diethylaminoethyl cellulose 
(selectacel 76, 0.8 mEq per gm; and .selectacel 70, 0.9 mEq per gm) were products  of Carl 
Schieicher and Schuell Co., Keene, New Hampshire.  Sephadex G-75, 100, and  200 were ob- 
tained from Pharmacia,  Uppsala, Sweden. Twice crystallized pepsin (Lot 673) and crystalline 
mercuripapain  (Lot 6102) were products of the Worthington  Biochemical Corp., Freehold, 
New Jersey. 
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elution from diethylaminoethyl cellulose columns previously equilibrated with 0.01  M phos- 
phate, pH 8. Concentrates of eluted fractions containing Bence Jones protein were separated 
from  any  major  contaminants  of  gamma  globulin  and  albumin  by  gel  filtration  using 
a sephadex G-100 column previously equilibrated with 0.1 M NaCI, 0.01 ~r phosphate, pH 8. 
Three urinary protein concentrates designated BJ protein 46, 47, and 48, originally obtained 
as ammonium sulfate precipitates from Dr. E. Osserman, were also passed  through similar 
sephadex G-100 columns under the same conditions. The Bence Jones proteins emerged as the 
third peak and readily separated from the first peak of 7S 3"-globulin and the small second peak 
of albumin. Other purified Bence Jones proteins were generously supplied by other investiga- 
tors and were used without further purification. Rabbit antisera to individual BJ proteins of 
the two major groups and to the s20.w =  5(5S)  fragment of pooled human "y2-globulin  (after 
pepsin  treatment,  vide infra)  were prepared  and used  to classify all of the BJ proteins by 
methods described previously (7). 
Isolation  of Serum  Protein  Fractions.--Pooled  normal T-globulin was  Cohn fraction  II 
(FII) Squibb lot 2001. 2 The 3'2-globulin  fraction and the macroglobulin-rich euglobulin frac- 
tion of individual normal sera were obtained by techniques described previously (8). 
Fragments of "y2-Globulins.-- 
Pepsin 5S fragment:  s~0,,o  =  5S  fragment  was  obtained  from pooled ")'s-globulin  after 
hydrolysis with pepsin at pit 4.0 for 24 hours by the method of Osterland et aL (9). This frag- 
ment was examined for residual intact 7S 3'2-globulins by utilizing the Gm a(+) quality of the 
pooled 3'2-globulin and analyzing the final product for its capacity to inhibit the agglutination 
of sheep  erythrocytes coated with  Gin a(+)  3'2-globulin  by a  serum having anfi-Gm  (a) 
specific rheumatoid factor (10). 
Pepsin 3.5S fragment: ss0.to =  3.5S fragment was obtained from the pepsin 5S fragment by 
reduction of this fragment with 0.1 ~ mercaptoethanol for 2 hours in a buffered saline solution 
at pH 8 and subsequent alkylation with iodoacetamide. Trace-contaminating 5S material was 
removed by passing the product  through a  sephadex G-200  column previously equilibrated 
with a buffered saline, pH 8. 
Papain 3.SSfragment:  The s20,,o =  315S fragment termed S by Edelman et al. (11) and A 
by Franklin (12) was formed after proteolysis of pooled "y-globulin with papain and a reducing 
agent. Residual 7S "y2-globulin was removed by gel filtration through sephadex G-200 and the 
A fragment isolated by anionic and cationic cellulose  ion exchange chromatography using a 
system similar to that described by Franklin (12). The absence of contamination of the final 
product with the F  (B) fragment was detected by using a previously described hemagglutina- 
tion system for the Gm a(+) antigen on this latter fragment (13). 
Fragments of 3'9_-Globulin Obtained by Reductive Methods.--The light (L) polypeptide chains 
of Cohn fraction II (FII) and of the 3.5S fragment (after pepsin treatment) were obtained by 
reduction using a variation of procedure 2 described by Edelman and Poullk (14). The reduc- 
tion was carried out in 0.2 ~ phosphate, pH 8, rather than in solutions containing urea. Alkyla- 
tion was with a  5-fold  molar excess of iodoacetamide. The L  chains of 7S 3'a-globulin  were 
obtained by gel filtration through a G-100 column using 0.5 M propionic acid for elution (15). 
The L chains  (the second peak) were recycled through a sephadex G-100 column to remove 
contaminating H chains. The L chains obtained from the 3.5S  fragment  (after pepsin  treat- 
ment) were separated from the fragments of the H chain by means of a sephadex G-75 column 
using 1.0 M propionic acid for equilibration and elution (16). 
Storage and Handling of Proteins.--Many proteins were stored as lyophilized preparations 
after dialysis against water. In most cases the lyophilized proteins were reconstituted in phos- 
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phate-buffered saline solution, pI-I 8. Other protein preparations were simply dialyzed against 
this buffered saline. All protein solutions were kept frozen prior to use. 
Sera.--Sera examined for agglutinating substances were obtained from apparently healthy 
laboratory personnel, patients on the general medical wards, as well as those attending the 
Arthritis Clinic of this hospital. The agglutinating characteristics of sera from patients with 
multiple myeloma, macroglobulinemia, and other neoplastic disease states  are not included 
in the present report. 
Serological Tests.-- 
Direct agglutination: The reference hemagglutination test system used in all studies was 
the FII hemagglutination procedure utilizing pooled commercial human Cotm fraction  II 
coated on tannic acid-treated  sheep erythrocytes by the method of Heller et al.  (17). Stand- 
ardization of these cells was carried out, using reference sera from patients with rheumatoid 
arthritis and all batches of cells showed similar sensitivity within one tube of serial dilution 
of reference agglutinator. Cells coated with purified Bence Jones proteins or with the L poly- 
peptide chain were prepared in a manner similar to that used for FII cells except that the 
coating protein was heated in a 1 mg per ml concentration at 55°C for 10 minutes prior to the 
coating procedure (see Results). Human thyroglobulin was prepared by the method of Spiro 
(18) and tanned cells coated with this protein were prepared by the method of Boyden (19). 
Dilution  of the agglutinating sera in doubling dilution  technique was carried out using a 1:2000 
concentration of fetal bovine serum (FBS) in pH 8-buffered saline as the diluent. The agglu- 
tination  pattern was read after 18 hours at 4°C. 
Inhibition tests: Serial doubling dilutions of inhibitors were carried out in the 1:2000 FBS 
diluent prior to the addition of an amount of agglutinator  showing two tubes of maximum 
agglutination in a control test. Inhibitor and agglutinator were maintained at 37°C for 1 hour 
and then at 4°C for 2 to 4 hours prior to the addition of protein-coated cells. Patterns were read 
as for direct agglutination. 
Sucrose  Density  Gradient Studies.--Continuous  linear sucrose gradient from 10 to 40 per 
cent was prepared as described by Edelman et al.  (20). Centrifugation of a 1:2 dilution of 
whole serum was in a Spinco model L machine at 35,000 ~PM for 15 hours. Drop samples were 
collected from a hole in the bottom of the tube. OD 280 was measured in a Beckman DU 
spectrophotometer. 
RESULTS 
The methods used for coating Bence Jones proteins or L chains in general 
followed those used previously for coating 7S "y2-globulins  when preservation of 
the  Gin specificity during the  coating process  was  essential  (21).  A  protein 
concentration of 1.0 mg of BJ protein or L  chain protein per ml of the buffered 
saline solution to which tannic acid-treated cells were added appeared  to give 
optimum coating and this concentration Was used for all studies in this report. 
Heating the  Bence Jones protein or L  chain preparations prior to coating ap- 
peared to be a  critical matter as regards reactivity with human but not rabbit 
agglutinators. Table I  presents the results obtained when variable durations of 
heat in a  constant bath temperature were applied to the BJ solutions prior to 
coating. The protein solution was heated in a  concentration of  1 mg of pro- 
tein/ml for  the  coating procedure.  Similar results were  obtained using the L 
chain of pooled normal 3,2-globulins as the cell-coating material. Studies which 
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20 minutes yielded no significant increase in activity of the coated cell.  Since 
there appeared no loss of group 1 or 2 specificities by this heating procedure, the 
application of 55°C of heat for 10 minutes just prior to the coating procedure 
has become routine in such studies. No increase in agglutinating capacity was 
found when using the euglobulin fraction in place of whole human serum as an 
agglutinator with cells coated with BJ proteins or L chains of pooled 72-globulin. 
Table II demonstrates  16 sera arranged according to ascending  FII titers. 
All have the capacity to agglutinate cells coated with one or another BJ pro- 
teins of the two major antigenic groups and/or with  the L  chains  of pooled 
TABLE  I 
Effect of Heating Benve Jones Proteins on Ability of Coated Cells to Detect A gglutinators 
Cell coated  with 
BJ protein, group 1, No. 40 
Not heated 
Heated 55°C, 5 min. 
Heated 55°C,  10 min. 
Heated 55°C,  15 min. 
BJ protein group 2, No. 43 
Not heated 
Heated 55°C, 5 min. 
Heated 55°C,  10 rain. 
Heated 55°C,  15 min. 
Rabbit anti-BJ pro- 
tein,  group I,  No. 40 
Log2 fiter* 
Rabbit anti-B~pro- 
teiu, group 2, No. 43  Human  serum 4918 
* Doubling dilutions of rabbit antisera begin at 1 : 200 and the human serum at 1: 20. 
normal Ts-globulin. It is apparent that some human sera can distinguish be- 
tween two BJ proteins both of group I (e.g. No. 7397) and two BJ proteins both 
of group 2 (e.g.  No. 6035) by agglutinating cells coated with only one of each 
pair. The log2 titer of a serum for BJ protein or L  chain-coated cells seems to 
bear no direct relationship to the log~ titer of the  serum for cells coated with 
pooled -r2-globulin.  The L  chain,  derived from the pooled ~/~-globulin,  has  a 
different pattern of activity as a cell coating than does the intact T2-molecule. 
There is, however, a trend for sera to show a higher titer for L chain-coated ceils 
the lower the FII titer and for sera to agglutinate L  chain coated-cells if they 
agglutinate cells coated with BJ protein of group 1. An additional expression 
of this latter relationship will be illustrated subsequently. 
Since some agglutinators in human sera appeared capable of reacting with 
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TABLE  II 
Log2 Titers of Human Sera*  Tested with  Various  Coated Cells 
Cell coating 
Serum 
L chains of  BJ protein,  [  BJ protein,  BJ protein,  BJ protein, 
Pooled 72(FII)  pooled 72  group 1, No. 40 group 1, No. 41 ~roup 2, No. 43 group 2, No. 44 
7471 
7374 
7343 
6035 
7397 
7213 
4918 
4766 
5157 
6286 
6054 
6382 
4983 
4671 
5490 
5685 
0 
0 
0 
0 
1 
6 
6 
8 
8 
10 
10 
11 
11 
13 
13 
13 
* First tube contains 1:20  dilution of sera. 
TABLE  III 
InMbigng  Capadty of Subunits of 7rGlobulin  and  of Bence Jones Proteins for Serum  4918 
Inhibitors* 
1.  Pooled FII 
2.  5S  fragment  of  inhibitor  1  after 
pepsin-acid treatment 
3.  3.5S  fragment  from  reduction  and 
alkylation of inhibitor 2 
4.  3.5S  (A-C)  fragment after  papain 
treatment of inhibitor 1 
5.  L  chain after  acid  dissociation  of 
inhibitor 3 
6.  BJ protein, group 1, No. 40 
7.  BJ protein, group 2, No. 43 
Number  of  tubes  showing  hemagglutinatlon  inhibition 
Cell  coating 
BJ  protein, 
group 1, No.  40 
BJ protein, 
group 2, No. 43  L chain of FII 
0 
0 
0 
0 
8 
2 
0 
* All inhibitors were in an initial concentration of 0.1 mg of protein/ml. 738  HUMAN  ANTIBODY  REACTING  WITH  BENCE  JONES  PROTEINS 
L  chains in the form of BJ proteins, while having no agglutinating activity 
toward intact'~'~-globulin,  it seemed possible that the involved L chain determi- 
nants were inaccessible in the intact molecule. 
Serum 4918 used in the study outlined by Table III is from a young woman 
with acute pyelonephritis. This serum demonstrates agglutinating capacity for 
several available BJ proteins of group 1, group 2, and L chains of pooled ~',-glob- 
ulin (FII). Concentrations of the serum which provide equal agglutinating ac- 
tivity for the three cell coatings shown were added to 2-fold dilutions of a series 
of potential inhibitors. All inhibitors were of the same protein concentration. 
The failure of intact "yg-globulin to affect inhibition has been confirmed at 
OD  280  --  1.0 using intact ~'~-globulin from ten normal individuals. A single 
"yiM-preparafion  of antigenic group  1 from a  patient with macroglobulinemia 
was equally ineffective as an inhibitor. Proteolysis of the F  portion of the H 
chains of "y~-globulin  by pepsin at pH 4.0 (inhibitor 2) failed to reveal the deter- 
minant sites on the L  chains.  Reduction and alkylation of the 5S  fragment 
produced by pepsin-acid treatment yielded an sg0,~ -- 3.5 fragment (inhibitor 3) 
and neither this nor a  similar product obtained directly from -y~-globulin by 
papain proteolysis (inhibitor 4) demonstrated any inhibitory capacity. It was 
only by acid dissociation of L chain from the fragment of H chain contained in 
the s~0.~, =  3.5 material that a material (inhibitor 5) was obtained which proved 
capable of competing with the L chain or BJ protein of group 1 coated on the 
cells for the agglutinators in serum 4918. L chain obtained directly from ~,2-glob- 
ulin behaved in a  manner indistinguishable from that of inhibitor 5. The BJ 
proteins which were capable of the specific inhibition shown in Table III had, 
of course, not been subject to the several procedures required to obtain in- 
hibitors  2  to 5.  The  ability of individual BJ proteins of group  1 to inhibit 
hemagglutination which  involved  cells  coated  with  the  L  chain  of  pooled 
v,-globulins appeared to be quite variable and depended in part on the par- 
ticular human serum used as the source of agglufinator. None of 14 BJ proteins 
of group 2 tested have demonstrated the capacity to inhibit hemagglutination of 
cells coated with L  chains of normal pooled ~,2-globulins. Neither have these 
14 BJ proteins of group 2 inhibited hemagglutination of cells coated with any 
of three BJ proteins of group 1. These two specificities  have been equally clear 
in the reverse situation. 
As shown in Table  II  selected sera  were capable,  by their direct hemag- 
glufinating specificity, of distinguishing between two BJ proteins belonging to 
the same group as established by rabbit  antisera to individual BJ proteins. 
In Tables IV a and IV b are shown subgroupings of groups 1 and 2 as log~ titers 
expressing the inhibitory capacity of BJ proteins. In Table IV a are six group 2 
BJ proteins tested against two different agglutinators of cells coated with BJ 
protein group 2, No. 46. The grouping of inhibitors and non-inhibitors is clearly 
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of the  agglutininators.  Sera which  can affect such  subdivision  of the major 
groups have to date been more easily found when studying group 2 rather than 
group 1 BJ proteins. An example of subgroupings of BJ proteins of group 1 by 
their inhibitory behavior is shown in Table IV b and again this delineation de- 
pends on the agglutinators and, in this case, the cell-coating material. 
TABLE  IVa 
Log2 Titer of Inki,  M,  tors for Group 2-Speeif~ Systems 
Inifibitors (initial  OD 280 ~  0.1) 
BJ protein, group 2 
No. 43 
No. 45 
No. 46 
No. 47 
No. 48 
No. 49 
Cell coating 
BJ protein, group 2, No. 46  BJ protein, group 2, No. 46 
Agglutinator serum 
5491  6042 
TABLE IV b 
Log2 Titer of InhibiZors  for Group 1-Spevific Systems 
Inhlbitors (initial OD 280 ~  0.2) 
BJ protein, group 1 
No. 39 
No. 40 
No. 41 
Cell costing 
BJ protein, group 1, No. 40  BJ protein, group 1, No. 41 
Agglutlnator serum 
4918  4893 
Nature  of the Agglutinating Substances  in Human Sera.--Of  some  100  sera 
found to demonstrate agglutinating specificity directed toward cells coated with 
the L  chains of normal pooled "y,-globulins  or BJ proteins of the two major 
groups, only one serum has had an hemagglutination titer greater than 1:1000. 
Twenty ~,2-globulin preparations from these sera obtained by anionic exchange 
chromatography have failed to demonstrate this hemagglutinafing  capacity. OD 280 
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18 
16 
14 
12 
I0 
8 
6 
4 
2 
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2  4  6  8  10  12  14  I6  CELL  COATING  TUBE 
74O 
!lTl]f  T:::::;:;T. 
POOLED  ~'£ GLOBULIN 
LOG2  HUMAN 
T I T E P,  THYROGLOBULI N 
.TTTTT  TT,T 
I  OJ PROTEIN 
_  TI?i/  ...........  GROUP  2,N0.4, 
Fro.  1.  Fractionation of serum 7501 by density gradient ultracentrifugation. Log2  titers 
of each tube fraction for three different coated cells. 
Agglutinating activity of the whole serum is markedly reduced or abolished by 
treatment with 0.1  •  mercaptoethanol for  8 hours.  The macroglobulin-rich 
fraction obtained by gel filtration of serum in low ionic strength buffer does 
reveal the agglutinating activity of the whole serum in titers comparable to 
that of the whole serum.  Fig.  1 demonstrates that on sucrose density ultra- 
centrifugation of a serum which demonstrated rheumatoid factor, thyroglobulin 
antibody, and BJ protein group 2 antibody activity, the agglutinators for BJ 
protein-coated cells have the same distribution as do the rheumatoid factors. 
These results appear to strongly suggest that the agglutinating factors for BJ WALLACE  V.  EPSTEIN  AND  DALE  GROSS  741 
protein and the L polypeptide chains found in human sera are macroglobulin 
7-globulins. 
DISCUSSION 
The experiments just described demonstrate that human sera may contain 
an agglutinating  substance or substances whose specificity is directed toward 
determinants  found on human  Bence Jones protein of both major antigenic 
groups.  Williams  (22)  has  reported  weak agglutinating  ability of some 19S 
rheumatoid factors for cells coated with the L chain of human or rabbit "),-glob- 
ulin, and in the present study this has been confirmed using the isolated L chains 
of pooled normal human "ys-globulins. Since the agglutinating substances appear 
to be contained within the macroglobulins and since  their specificity is directed 
toward a naturally occurring constituent of human T-globulins, past argmnents 
for human rheumatoid factors being antibody (iso- and/or auto-) are applicable 
to  these  agglutinators.  These  arguments  have  recently  been  presented  in 
detail (23). 
The necessity for heating the protein just prior to coating on cells suggests 
similar  observations made when coating ~,-globulins of known Gin type (10, 
21). In both instances rabbit 7S antibody to the material used for cell coating 
reacted with cells coated with unheated protein, while only cells coated with 
previously heated protein were agglutinated by agglutinators found in human 
sera.  It appears likely that both the application of heat and the actual cell- 
coating procedure result in conformational changes of the coating protein which 
allow  interaction  with macroglobulin  antibody.  Whatever  the nature  of the 
change produced by heat, it is interesting that such a change had not occurred 
during the several relatively drastic chemical steps required in the preparation 
of the L polypeptide chains of human -y2-globulins or if the change had occurred 
it was reversible.  That conformational changes in Bence Jones proteins occur at 
the temperature used in this study recently has been demonstrated by G~lly 
and Edelman (24) in their measurements of the fluorescence of heated BJ pro- 
teins. The essential role  of what are probably conformational factors on the 
serological activity of globulin-coated cells has been demonstrated by Pirofsky 
e/a/. (25). In prior studies of Gin-specific -}~,-globulins coated on tanned cells, it 
was found that the euglobulin  fraction of some sera could cause hemagglutina- 
tion when the whole serum could not (21) thus suggesting an autoinhlbitory 
phenomenon.  Similar  attempts  to use the euglobulin fraction of sera which 
fail to or weakly agglutinate  cells coated with BJ or L  chain protein failed to 
indicate autoinhibition for this system. Although limited in number, the sera 
presented in Table II illustrate that human agglutinators for BJ proteins are 
distinct from antibody to H  chain determinants.  All attempts to prove that 
coating  T~-globulin on cells  exposes  the L  chain  sites toward which human 
antibody appears directed have failed.  In no instance have L  chains or any 
examined BJ protein been capable of inhibiting the hemagglutination reaction 742  HUMAN  ANTIBODY  REACTING  WITH  BENCE  JONES  PROTEIN 
between q,~-globulin-coated cells and naturally occurring human agglutinators. 
Table II is meant only to illustrate the problem of subgroup classification as it 
is emerging since it is not possible to assemble a panel of BJ proteins of the 
two major groups which we could be certain would detect agglutinators for all 
possible subgroups.  For this same reason,  nothing in this report is meant to 
imply knowledge of the distribution of BJ protein antibody in human sera by 
age, family relationship,  or clinical state. 
That the specificity of these agglutinators conforms to the two major BJ 
protein groups is best illustrated in the failure, to date, of a BJ protein of one 
group to inhibit a test system in which a human serum causes agglutination of 
cells coated with a BJ protein of the other group (Table III). The use of natu- 
rally occurring human antibody would appear to extend the complexity of the 
BJ protein subgroup  classification beyond that suggested by rabbit antisera 
using  precipitation techniques  (26). From Table  IV a  it would  appear  that 
serum 5491 has agglutinating specificity for a determinant of BJ group 2 pro- 
tein No. 46, different from that of serum 6042. It is by the extension of this 
technique  that one might elaborate  the determinant mosaic within each major 
antigenic group. That this subgrouping may be more complex for group 2 than 
group 1 is suggested by the work of Putnam et al.  (27) using pepfide maps of 
BJ proteins of the two major antigenic groups, by Stein el al. (26) using double 
diffusion studies in agar with rabbit antisera to Bence Jones proteins, and in the 
present study by the difficulty  in finding agglutinators which distinguish among 
BJ proteins of group  1 compared to the ease in finding discriminating  sera for 
group 2. These results are also explainable, however, by the possibility that the 
particular BJ proteins of group 1 currently available share many determinants 
of the same subgroup.  Failure to observe cross-reactivity  between any Bence 
Jones protein of group  2 and L chain of pooled v~-globulin while such cross- 
reactivity is observed with BJ proteins of group 1 and L chains suggests the 
greater individuality of members of group 2 and therefore the probability that 
there would not be a sufficient concentration of a given subgroup in the L chains 
of pooled ~,2-globulins to compete  with the homogeneous population of a  BJ 
group 2 protein. 
The presence  of human antibody to configurations  of human "y~-globulin 
which  are blocked  in the intact molecule has been  demonstrated previously 
using  the  "5S"  fragment obtained by the pepsin-acid  treatment of human 
~,~-globulin (9, 28). Cells coated with such fragments are agglutinated by select 
human sera and this hemagglutination is not inhibited by intact ~,9:globulin or 
isolated L chains. The results shown in Table III indicate that it is the portion of 
the H chains which survives proteolysis using pepsin that furnishes the steric 
obstruction to the L chain determinants. After reduction of the 5S fragment, 
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and is still capable of the obstruction of the determinants toward which this 
antibody is directed. 
Although the explanation just presented makes possible the concept of the 
simultaneous circulation of intact ~,-globulins  and antibodies to obstructed L 
chain sites, it does not deal with what have been described as free L chains pres- 
ent  in small amounts in normal  sera  (29).  The source and time of antigenic 
stimulus for the antibody system just described is, as yet, unknown. Prelimi- 
nary observations of human umbilical cord blood indicate detectable levels of 
these  macroglobulin antibodies  present  at  birth.  This  fact, together with a 
specificity of such antibody directed toward determinant groups present on all 
classes of immune globulins, suggests the possibility of an homeostatic system. 
The  biological  significance of human  antibody to  exposed  determinants  of 
human ~/-globulins such as the Gm and InV sites as well as the significance of 
antibody to buried or obstructed determinants such as those just described re- 
main a problem for continued investigations. 
SIy~rMAR¥ 
Agglutinating substances having characteristics of naturally occurring macro- 
globulin antibodies to human Bence  Jones  proteins have  been  identified in 
human sera. By means of hemagglutination and hemagglutination inhibition 
techniques, common determinants have been demonstrated on the light  (L) 
polypeptide chains of pooled normal human ^/2-globulin and on some Bence 
Jones proteins of group 1 but not of group 2. Individual human sera serve to 
delineate subgroups of the two major antigenic groups of the Bence Jones pro- 
teins by agglutinating cells coated by one but not another protein of the same 
antigenic group. The complexity of subgroups, especially of group 2, is estab- 
lished by testing a panel of Bence Jones proteins of the same group for their 
ability to inhibit hemagglutination. By this means it appeared that different 
sera  recognized different group-specific  determinants  of  cells  coated  with  a 
single Bence Jones protein. 
The  capacity  of  the  L  polypeptide  chains  and  proteolytic  fragments  of 
"y2-globulin to inhibit the hemagglutination reaction between Bence Jones pro- 
tein  or  L  chain-coated cells  and human sera  was  examined. These  studies 
demonstrated that  the determinants, toward which agglutinators of human 
serum are directed, appear to be blocked in intact v2-globulin and in all frag- 
ments in which H  chain remains in proximity to L chain. It would appear that 
the presence of H  chains bound to L chains by non-covalent bonds completely 
obstructs the reactivity of the involved L chain groups. The agglutinating ca- 
pacity of a  serum toward Bence Jones proteins or L  chains of 7~-globulin  ap- 
peared  to be independent of its agglutinating capacity for cells  coated with 
intact ~,2-globulin. No correlation of the presence in serum of agglutinators for 
Bence Jones proteins or L chains with health or disease has been established. 744  HUMAN  ANTIBODY REACTING WITH BENCE JONES PROTEIN 
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Note Added in Proof.--Since  submission of this manuscript,  R.  C. Williams, Jr., 
(Proc. Nat. Acad. Sc., 1954, 52, 60) has reported on agglutinators in the sera of per- 
sons with rheumatoid arthritis which react with Bence Jones protein coated cells. His 
report finds no correlation of agglutinating activity with the InV (a) type of the Bence 
Jones proteins. 
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